๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Cancer therapy and the randomized clinical trial good medicine?

โœ Scribed by Dwight Kaufman


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
465 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Limitations of the randomized trial for
โœ Charles R. Smart ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB ๐Ÿ‘ 2 views

the National Cancer Advisory Board of the National Cancer Institute (NCI), made a statement regarding randomized clinical trials (RCTs) that, although helpful in some circumstances, they were not always possible and that clinical judgment coupled with descriptive and other types of studies were also

The quest for unbiased research: Randomi
โœ Dr Kenneth F. Schulz ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 487 KB ๐Ÿ‘ 1 views

## Abstract The large and increasing number of randomized clinical trials in all of medicine has prompted the introduction of guidelines that are intended to improve the quality of the research and of the published papers derived from such investigations. These guidelines for reporting clinical tri

Randomized population trials and screeni
โœ Gary M. Strauss ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 212 KB ๐Ÿ‘ 1 views

## BACKGROUND. At the current time, there is nearly universal agreement that screening for the early detection of lung carcinoma is not justified. This is based on the fact that, to the author's knowledge, no randomized population trial (RPT) to date has demonstrated a significant reduction in lun

Hybrid cell vaccination for cancer immun
โœ Uwe Trefzer; Guido Weingart; Yingwen Chen; Gunda Herberth; Karin Adrian; Helmut ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 364 KB ๐Ÿ‘ 2 views

Hybrid cell vaccination is a new cancer immune therapy approach that aims at recruiting T cell help for the induction of tumour specific cytolytic immunity. The vaccines are generated by fusion of the patients' tumour cells with allogeneic MHC class II bearing cells to combine the tumour's antigenic